A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)

Background: Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents that use monoclonal antibodies to specifically recognize tumour cell surface antigens. However, off-target effects may lead to severe adverse events. This study evaluated the neurotoxicity of ADCs using the F...

Full description

Bibliographic Details
Main Authors: Linlin Tang, Cuicui Sun, Wenshan Liu, Haiyan Wu, Chuanhua Ding
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Pharmacology
Subjects:
antibody-drug conjugates (ADCs)
neurotoxicity
FAERS
pharmacovigilance
data mining
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1362484/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1362484/full

Similar Items